Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent

• Published in: Urologic oncology 2015-04, Vol.33 (4), p.166.e21-166.e29
• Main Authors: Merrill, Megan M., D.O, Wood, Christopher G., M.D., F.A.C.S, Tannir, Nizar M., M.D., F.A.C.P, Slack, Rebecca S., M.S, Babaian, Kara N., M.D, Jonasch, Eric, M.D, Pagliaro, Lance C., M.D, Compton, Zachary, M.D, Tamboli, Pheroze, M.D, Sircar, Kanishka, M.D, Pisters, Louis L., M.D, Matin, Surena F., M.D., F.A.C.S, Karam, Jose A., M.D., F.A.C.S
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell - mortality; Carcinoma, Renal Cell - pathology; Carcinoma, Renal Cell - surgery; Cell Dedifferentiation; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms - mortality; Kidney Neoplasms - pathology; Kidney Neoplasms - surgery; Male; Middle Aged; Nephrectomy; Renal cell carcinoma; Sarcomatoid; Treatment Outcome; Urology
• ISSN: 1078-1439; 1873-2496
• DOI: 10.1016/j.urolonc.2014.11.021

Abstract Purpose Renal cell carcinoma with sarcomatoid dedifferentiation (sRCC) is an aggressive malignancy associated with a poor prognosis. Although existing literature focuses on patients presenting with metastatic disease, characteristics and outcomes for patients with localized disease are not well described. We aimed to evaluate postnephrectomy characteristics, outcomes, and predictors of survival in patients with sRCC who presented with clinically localized disease. Patients and methods An institutional review board–approved review from 1986 to 2011 identified 77 patients who presented with clinically localized disease, underwent nephrectomy, and had sRCC in their primary kidney tumor. Clinical and pathologic variables were captured for each patient. Overall survival (OS) and recurrence-free survival (RFS) were calculated for all patients and those who had no evidence of disease (NED) following nephrectomy, respectively. Comparisons were made with categorical groupings in proportional hazards regression models for univariable and multivariable analyses. Results OS for the entire cohort ( n = 77) at 2 years was 50%. A total of 56 (77%) patients of the 73 who has NED following nephrectomy experienced a recurrence, with a median time to recurrence of 26.2 months. On multivariable analysis, tumor stage, pathologically positive lymph nodes, and year of nephrectomy were significant predictors of both OS and recurrence-free survival. Limitations include the retrospective nature of this study and relatively small sample size. Conclusions Long-term survival for patients with sRCC, even in clinically localized disease, is poor. Aggressive surveillance of those who have NED following nephrectomy is essential, and further prospective studies evaluating the benefit of adjuvant systemic therapies in this cohort are warranted.